Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Letter
  • Published:

Spironolactone increases serum uric acid levels in patients with chronic kidney disease

Journal of Human Hypertension volume 28, pages 210–211 (2014)Cite this article

Subjects

Raised serum uric acid levels are associated with increased cardiovascular risk in many patient groups, including those with chronic kidney disease. Mineralocorticoid receptor antagonists are showing great promise as a means of lowering cardiovascular risk in patients with chronic kidney disease; yet their actions on serum uric acid are not known. The present study examined the actions of the mineralocorticoid receptor antagonist spironolactone on serum uric acid in patients with early chronic kidney disease.

Several studies have demonstrated a relationship between raised serum uric acid levels and multiple cardiovascular (CV) conditions including hypertension and chronic kidney disease (CKD). Emerging data suggest that lowering serum uric acid levels might have both CV and renal benefits.1 The mineralocorticoid hormone aldosterone has also been implicated in the pathophysiology of both CV disease and CKD.2 However, studies of mineralocorticoid receptor antagonism have shown conflicting results on serum uric acid levels.3, 4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Feig DI, Kang D-H, Johnson RJ . Uric acid and cardiovascular risk. N Engl J Med 2008; 359 (17): 1811–1821.

    Article  CAS  Google Scholar 

  2. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. JACC 2009; 54 (6): 505–512.

    Article  CAS  Google Scholar 

  3. Schrijver G, Weinberger MH . Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979; 25 (1): 33–42.

    Article  CAS  Google Scholar 

  4. Falch DK, Schreiner A . The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand 1983; 213 (1): 27–30.

    Article  CAS  Google Scholar 

  5. Shibutani Y, Ueo T, Takahashi S, Moriwaki Y, Yamamoto T . Effect of ACTH on renal excretion of purine bases in a patient with isolated ACTH deficiency. Clin Chim Acta 2000; 294 (1-2): 185–192.

    Article  CAS  Google Scholar 

  6. Namba M, Kikuchi K, Komura H, Suzuki S, Satoh N, Ohtomo T et al. Study on uric acid metabolism in patients with primary aldosteronism. Nihon Naibunpi Gakkai Zasshi 1992; 68 (1): 51–61.

    CAS  PubMed  Google Scholar 

  7. Anzai N, Endou H . Urate transporters: an evolving field. Semin Nephrol 2011; 31 (5): 400–409.

    Article  CAS  Google Scholar 

  8. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem 2004; 279 (44): 45942–45950.

    Article  CAS  Google Scholar 

  9. Lamprecht G, Hsieh C-J, Lissner S, Nold L, Heil A, Gaco V et al. Intestinal anion exchanger down-regulated in adenoma (DRA) is inhibited by intracellular calcium. J Biol Chem 2009; 284 (284): 19744–19753.

    Article  CAS  Google Scholar 

  10. Ruggenenti P, Cravedi P, Remuzzi G . Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23 (12): 1917–1928.

    Article  CAS  Google Scholar 

  11. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension 2011; 58 (1): 2–7.

    Article  CAS  Google Scholar 

  12. Dhaun N, Webb DJ . Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2012; 59 (1): e1.

    Article  CAS  Google Scholar 

  13. Talaat KM, el-Sheikh AR . The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27 (5): 435–440.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology Section, Clinical Hospital, Universidad de Chile and Critical Care Center, Clínica las Condes, Santiago, Chile

    S E Cabrera

  2. Department of Cardiology, University Hospital Birmingham, University of Birmingham, Birmingham, UK

    N C Edwards, R P Steeds & J N Townend

  3. Department of Nephrology, University Hospital Birmingham, University of Birmingham, Birmingham, UK

    C J Ferro

Authors
  1. S E Cabrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N C Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R P Steeds
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J N Townend
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C J Ferro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C J Ferro.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cabrera, S., Edwards, N., Steeds, R. et al. Spironolactone increases serum uric acid levels in patients with chronic kidney disease. J Hum Hypertens 28, 210–211 (2014). https://doi.org/10.1038/jhh.2013.66

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2013.66

Search

Advanced search

Quick links